Ophthalmology company InSite Vision is opting to take an all-cash bid from an undisclosed bidder than go through with its merger with Canadian biotech QLT – resulting in a second deal that the biotech can't get done.
InSite announced Aug. 21 that its board of directors had determined that the 25 cents per share offer from an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?